FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311281430> ?p ?o ?g. }

• W4311281430 endingPage "5993" @default.
• W4311281430 startingPage "5993" @default.
• W4311281430 abstract "Despite its relative low incidence, PDAC is one of the most aggressive and lethal types of cancer, being currently the seventh leading cause of cancer death worldwide, with a 5-year survival rate of 10.8%. Taking into consideration the necessity to improve the prognosis of these patients, this research has been focused on the discovery of new biomarkers. For this purpose, patients with BL and resectable disease were recruited. Serum cytokines and growth factors were monitored at different time points using protein arrays. Immune cell populations were determined by flow cytometry in peripheral blood as well as by immunohistochemistry (IHC) in tumor tissues. Several cytokines were found to be differentially expressed between the study subgroups. In the BL disease setting, two different scores were proven to be independent prognostic factors for progression-free survival (PFS) (based on IL-10, MDC, MIF, and eotaxin-3) and OS (based on eotaxin-3, NT-3, FGF-9, and IP10). In the same context, CA19-9 was found to play a role as independent prognostic factor for OS. Eotaxin-3 and MDC cytokines for PFS, and eotaxin-3, NT-3, and CKβ8-1 for OS, were shown to be predictive biomarkers for nab-paclitaxel and gemcitabine regimen. Similarly, oncostatin, BDNF, and IP10 cytokines were proven to act as predictive biomarkers regarding PFS, for FOLFIRINOX regimen. In the resectable cohort, RANTES, TIMP-1, FGF-4, and IL-10 individually differentiated patients according to their cancer-associated survival. Regarding immune cell populations, baseline high levels of circulating B lymphocytes were related to a significantly longer OS, while these levels significantly decreased as progression occurred. Similarly, baseline high levels of helper lymphocytes (CD4+), low levels of cytotoxic lymphocytes (CD8+), and a high CD4/CD8 ratio, were related to a significantly longer PFS. Finally, high levels of CD4+ and CD8+ intratumoural infiltration was associated with significantly longer PFS. In conclusion, in this study we were able to identify several prognostic and predictive biomarker candidates in patients diagnosed of resectable or BL PDAC." @default.
• W4311281430 created "2022-12-25" @default.
• W4311281430 creator A5000204001 @default.
• W4311281430 creator A5009934241 @default.
• W4311281430 creator A5012440329 @default.
• W4311281430 creator A5017427348 @default.
• W4311281430 creator A5031039134 @default.
• W4311281430 creator A5045435529 @default.
• W4311281430 creator A5048670628 @default.
• W4311281430 creator A5048699077 @default.
• W4311281430 creator A5052641685 @default.
• W4311281430 creator A5058477880 @default.
• W4311281430 creator A5059027410 @default.
• W4311281430 creator A5060205533 @default.
• W4311281430 creator A5076205150 @default.
• W4311281430 creator A5078617469 @default.
• W4311281430 creator A5080476285 @default.
• W4311281430 creator A5081857626 @default.
• W4311281430 creator A5088309104 @default.
• W4311281430 date "2022-12-05" @default.
• W4311281430 modified "2023-10-10" @default.
• W4311281430 title "Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma" @default.
• W4311281430 cites W1952821838 @default.
• W4311281430 cites W1979358785 @default.
• W4311281430 cites W1986900295 @default.
• W4311281430 cites W2000770184 @default.
• W4311281430 cites W2001781773 @default.
• W4311281430 cites W2022232864 @default.
• W4311281430 cites W2024246831 @default.
• W4311281430 cites W2077854254 @default.
• W4311281430 cites W2085138770 @default.
• W4311281430 cites W2106837613 @default.
• W4311281430 cites W2107780185 @default.
• W4311281430 cites W2125104845 @default.
• W4311281430 cites W2263966141 @default.
• W4311281430 cites W2281452671 @default.
• W4311281430 cites W2393564993 @default.
• W4311281430 cites W2463195069 @default.
• W4311281430 cites W2553172239 @default.
• W4311281430 cites W2623274890 @default.
• W4311281430 cites W2745604389 @default.
• W4311281430 cites W2771915140 @default.
• W4311281430 cites W2775759880 @default.
• W4311281430 cites W2794353934 @default.
• W4311281430 cites W2795125785 @default.
• W4311281430 cites W2807864393 @default.
• W4311281430 cites W2889646458 @default.
• W4311281430 cites W2897141769 @default.
• W4311281430 cites W2917919815 @default.
• W4311281430 cites W2926499479 @default.
• W4311281430 cites W2978682544 @default.
• W4311281430 cites W2989679719 @default.
• W4311281430 cites W2997794888 @default.
• W4311281430 cites W3027648247 @default.
• W4311281430 cites W3039596546 @default.
• W4311281430 cites W3039671381 @default.
• W4311281430 cites W3042679490 @default.
• W4311281430 cites W3046664040 @default.
• W4311281430 cites W3047135849 @default.
• W4311281430 cites W3083101162 @default.
• W4311281430 cites W3086286991 @default.
• W4311281430 cites W3086754792 @default.
• W4311281430 cites W3089070233 @default.
• W4311281430 cites W3116476232 @default.
• W4311281430 cites W3127664533 @default.
• W4311281430 cites W3128646645 @default.
• W4311281430 cites W3129075084 @default.
• W4311281430 cites W4251725022 @default.
• W4311281430 cites W4285491831 @default.
• W4311281430 doi "https://doi.org/10.3390/cancers14235993" @default.
• W4311281430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36497475" @default.
• W4311281430 hasPublicationYear "2022" @default.
• W4311281430 type Work @default.
• W4311281430 citedByCount "0" @default.
• W4311281430 crossrefType "journal-article" @default.
• W4311281430 hasAuthorship W4311281430A5000204001 @default.
• W4311281430 hasAuthorship W4311281430A5009934241 @default.
• W4311281430 hasAuthorship W4311281430A5012440329 @default.
• W4311281430 hasAuthorship W4311281430A5017427348 @default.
• W4311281430 hasAuthorship W4311281430A5031039134 @default.
• W4311281430 hasAuthorship W4311281430A5045435529 @default.
• W4311281430 hasAuthorship W4311281430A5048670628 @default.
• W4311281430 hasAuthorship W4311281430A5048699077 @default.
• W4311281430 hasAuthorship W4311281430A5052641685 @default.
• W4311281430 hasAuthorship W4311281430A5058477880 @default.
• W4311281430 hasAuthorship W4311281430A5059027410 @default.
• W4311281430 hasAuthorship W4311281430A5060205533 @default.
• W4311281430 hasAuthorship W4311281430A5076205150 @default.
• W4311281430 hasAuthorship W4311281430A5078617469 @default.
• W4311281430 hasAuthorship W4311281430A5080476285 @default.
• W4311281430 hasAuthorship W4311281430A5081857626 @default.
• W4311281430 hasAuthorship W4311281430A5088309104 @default.
• W4311281430 hasBestOaLocation W43112814301 @default.
• W4311281430 hasConcept C121608353 @default.
• W4311281430 hasConcept C126322002 @default.
• W4311281430 hasConcept C13373296 @default.
• W4311281430 hasConcept C143998085 @default.
• W4311281430 hasConcept C151730666 @default.

• next